starpharma | home
home
about starpharma
technology
product pipeline
news room
investor relations
 careers contact us
site search
News Room
 
 
 February 2010
Appendix 3B
9/02/2010
Starpharma and Lilly Sign New Drug Delivery Collaboration
1/02/2010
 January 2010
Appendix 4C - quarterly
29/01/2010
Appendix 3B
28/01/2010
Appendix 3B
21/01/2010
Lapse of Unquoted Options
5/01/2010
 November 2009
Becoming a Substantial Holder - Orbis Australia
24/11/2009
Cleansing Statement
24/11/2009
Appendix 3B
24/11/2009
Starpharma announces $15.6 million capital raising
18/11/2009
Suspended at the request of company
16/11/2009
Results of Meeting
13/11/2009
AGM Chairman`s and CEO`s Presentations
12/11/2009
Starpharma signs agrochemicals deal
5/11/2009
 October 2009
New legislation results in withdrawal of CEO incentive schem
29/10/2009
Appendix 4C - Quaterly Report
23/10/2009
Notice of Annual General Meeting/Proxy Form
13/10/2009
 September 2009
2009 Annual Report (1.1 MB)
30/09/2009
US Patent Grant Extends VivaGel Coverage to 2024
22/09/2009
Release of Shares From Escrow
18/09/2009
Shareholder Update
17/09/2009
 August 2009
Preliminary Final Report
24/08/2009
Interim Financial Results - Material Improvement
4/08/2009
VivaGel - Anti-HIV and Herpes Activity following Human Admin
3/08/2009
 July 2009
Appendix 4C - Quarterly Report
27/07/2009
 June 2009
Appendix 3B - Employee Share Options
30/06/2009
Lapse of Unquoted Options
30/06/2009
Shareholder Update June 2009
2/06/2009
 May 2009
Change in substantial holding
25/05/2009
Cleansing Statement
22/05/2009
Appendix 3B
22/05/2009
Appendix 3B
22/05/2009
Completes $7.1m capital raising
21/05/2009
CEO Investor Presentation
13/05/2009
Elanco Deal Triggers Starpharma SPP Extension
11/05/2009
Starpharma and Elanco Sign Agreement
11/05/2009
Share Purchase Plan Extension
5/05/2009
 April 2009
Shareholder Update May 2009
30/04/2009
Share Purchase Plan
22/04/2009
Change in Substantial Holding
16/04/2009
Cleansing Statement
8/04/2009
Appendix 3B
8/04/2009
Appendix 4C - Quarterly Report
7/04/2009
Raises Additional Capital via Institutional Placement
7/04/2009
Trading Halt
3/04/2009
 March 2009
Completes patient testing in retention of activity study
19/03/2009
 February 2009
2008 Half Yearly Report and Half Year Accounts (0.2MB)
19/02/2009
Topical Microbicide Field Boost With Efficacy Result
10/02/2009
Lapse of unquoted options
9/02/2009